GET DAILY SIGNALSIDEXX Laboratories (IDXX) Shares Climb +35% on Strong Q3 Results and Raised Outlook
Key Takeaways
- IDEXX Laboratories shares climbed roughly 35% over the past 30 days, rising from about $520 to above $700.
- The advance was driven primarily by a stronger-than-expected third-quarter earnings report and a raised full-year outlook announced in early November.
- Third-quarter revenue rose 10% organically to approximately $1.21 billion, while diluted EPS of $4.01 increased 18% on a reported basis and 22% on a comparable basis.
- Companion Animal Group diagnostics recurring revenue grew 11% organically, led by 14% growth in international markets.
- The company raised its full-year 2026 revenue and earnings-per-share guidance for the third time this year.
- Shares rallied even as U.S. same-store clinical visits declined an estimated 1.8% in the quarter, reflecting higher testing intensity per visit.
- For deeper data on this ticker, explore Price Targets, Earnings, and Forecast pages for additional analysis.
- For automated trading insights across the market, explore Trending AI Robots.
Understanding IDEXX Laboratories’ Business and Market Position
IDEXX Laboratories, headquartered in Westbrook, Maine, leads globally in veterinary diagnostics. Companion animal diagnostics make up roughly 92% of net sales, with smaller contributions from water-quality testing and livestock, poultry, and dairy segments. The company provides diagnostic instruments, recurring consumables for veterinary clinics, reference laboratory services, and practice-management software.
Its strength lies in a razor-and-blade approach: once clinics install analyzers like the inVue Dx or Catalyst platforms, they typically reorder consumables for years. This creates a stable recurring revenue stream. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors track the name closely because the model has supported durable double-digit growth even when clinic traffic softens.
IDEXX Laboratories (IDXX) Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, IDXX advanced approximately 35%, moving from a close near $520 to above $700. Most of the move came in one session in early November after the third-quarter report.
The three-month picture showed more volatility. Shares started near $567 in early August, slipped to the low $500s by mid-September on concerns about pet-clinic visits, then recovered through October before the earnings surge. Overall, the stock finished up roughly 24% over the trailing quarter.
What Pushed IDXX Higher in the Last 30 Days
The main driver was the third-quarter earnings release in early November. Revenue reached about $1.21 billion, up 10% both reported and organically, topping consensus near $1.19 billion. Diluted EPS of $4.01 beat estimates and rose 18% year over year, while net income grew 16% to roughly $317 million.
Companion Animal Group diagnostics recurring revenue rose 11% organically, with international markets up 14%. Gross margin expanded to 62.9% and operating margin to 33.1%, each improving about 100 basis points. IDEXX raised full-year 2026 revenue guidance to $4.741 billion–$4.767 billion and EPS guidance to $14.96–$15.16. From what I see, the market responded not only to the beat but also to evidence that diagnostics revenue can grow through higher testing per visit and new products even when traffic is soft. The company placed more than 1,900 inVue Dx analyzers and completed the CoVet acquisition.
Factors Behind Performance Over the Trailing Quarter
The broader three-month period featured two distinct phases. From August into September, shares fell as investors focused on weaker U.S. clinic visits, slower puppy and kitten adoption, and pricing questions. The stock dropped from the mid-$560s toward the low $500s.
The tone changed in November. Third-quarter results highlighted the recurring revenue model’s resilience, and the raised outlook led investors to re-rate the shares. At least one analyst firm raised its price target while keeping a neutral rating. The move also aligned with a broader shift toward healthcare and consumer-related names.
Key Items to Watch for IDXX Going Forward
Investors will likely focus on whether double-digit organic growth can continue while U.S. clinic visits stay soft. Fourth-quarter and full-year results versus the updated guidance, adoption of inVue Dx and the Cancer Dx panel, and integration of the CoVet deal—which brings near-term EPS dilution—will matter. International momentum, competitive pressures, pricing trends, and consumer spending on pets remain important. These are monitoring points, not a basis for any specific investment decision. I’m watching this closely through Tickeron’s AI Trend Prediction Engine to track potential pattern shifts.
Using AI Tools in My Research Process
When evaluating stocks like this one, I sometimes review Tickeron’s automated trading resources to see how different strategies have performed on similar names. The platform offers a range of AI-driven bots that cover thousands of tickers, with filters for strategy, timeframe, and results. It gives a practical way to compare approaches without replacing individual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
IDXX in +5.36% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IDXX advanced for three days, in 178 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 53 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 97 of 171 cases where IDXX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. IDXX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.027) is normal, around the industry mean (67.298). P/E Ratio (47.242) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties
Advertisement